SecBot SecBot
S-3 ·Filed Nov 16, 2026

ACRV

Acrivon Therapeutics, Inc.
NEUTRAL
Impact 3/10
Horizonmonths Processed1d ago SEC0001193125-26-463828
Shelf registration (potential dilution)
Actionable Insight • Neutral

Monitor for prospectus supplements that would indicate actual capital raise size and terms. The shelf gives management flexibility but the I.B.6 limit restricts primary sales to ~$11.5M in any 12-month period given the current $34.6M public float, unless the float increases or the company qualifies for full shelf access.

DirectionNeutral
Confidencehigh
Horizonmonths
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Acrivon Therapeutics filed a new S-3 shelf registration statement for up to $300 million in securities (common stock, preferred stock, debt securities, warrants, units), replacing a prior shelf with $292.7 million of unsold securities carried forward. The filing comes on the same day as Q3 2026 results showing $77.8 million in cash, expected to fund operations into Q4 2027, and no immediate pricing or offering was announced. The shelf provides broad financing flexibility for a clinical-stage biotech with no revenue and ongoing losses.

Key Financial Metrics

Offering Size
$300.0M

Key Facts

  • S-3 shelf registration filed for up to $300,000,000 in aggregate securities
  • $292,701,082.80 of unsold securities carried forward from prior S-3 (File No. 333-275854)
  • $7,298,917.20 of newly registered securities; registration fee of $635.01
  • Filed on same day as Q3 2026 earnings release and 10-Q
  • Cash, cash equivalents, and marketable securities of $77.8 million as of September 30, 2026
  • Company expects cash to fund operations into Q4 2027
  • Public float approximately $34.6 million; subject to I.B.6 one-third public float limit on primary sales
  • No specific offering, pricing, or terms announced in the filing

Financial Impact

Shelf registration of up to $300 million; no immediate capital raise. Company had $77.8M cash as of Sept 30, 2026.

dilutiondebtequity

Risk Factors

  • Potential future dilution from any equity or convertible issuance under the shelf
  • Company is pre-revenue with recurring losses; may need to access this shelf for funding
  • I.B.6 restriction limits primary sales to ~one-third of public float ($34.6M) in any 12-month period

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
S-3 Filing (Primary)0001193125-26-463828
Document: d185923dex43.htm0001193125-26-463828
Document: d185923dexfilingfees.htm0001193125-26-463828
Document: d185923dex51.htm0001193125-26-463828
Document: d185923dex231.htm0001193125-26-463828
Document: 0001193125-26-463828-index-headers.html0001193125-26-463828

US Market Status

Market Closed · Opens Wed (< 1m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 16, 2026